{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:14:43Z","timestamp":1789820083479,"version":"4.0.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011151","name":"American Academy of Ophthalmology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.oret.2024.04.016","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T01:53:05Z","timestamp":1713837185000},"page":"953-961","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Loss to Follow up in Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and\/or Panretinal Photocoagulation in the United States"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5198-1353","authenticated-orcid":false,"given":"Rahul N.","family":"Khurana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Lum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2024.04.016_bib1","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.04.016_bib2","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.oret.2024.04.016_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0002-9394(98)00309-2","article-title":"Causes of severe visual loss in the Early Treatment Diabetic Retinopathy Study: ETDRS report no. 24","volume":"127","author":"Fong","year":"1999","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.04.016_bib4","first-page":"397","article-title":"Preliminary report on effects of photocoagulation therapy","volume":"81","year":"1976","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.04.016_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/eme05050","article-title":"Intravitreal aflibercept compared with panretinal photocoagulation for proliferative diabetic retinopathy: the CLARITY non-inferiority RCT","volume":"5","author":"Sivaprasad","year":"2018","journal-title":"Effic Mech Eval"},{"key":"10.1016\/j.oret.2024.04.016_bib6","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jcjo.2021.01.017","article-title":"Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis","volume":"56","author":"Yates","year":"2021","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.oret.2024.04.016_bib7","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.oret.2024.04.016_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2021.100037","article-title":"Temporal trends in the treatment of proliferative diabetic retinopathy: an AAO IRIS\u00ae registry analysis","volume":"1","author":"Gong","year":"2021","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2024.04.016_bib9","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1111\/j.1755-3768.2011.02184.x","article-title":"Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for high-risk proliferative diabetic retinopathy","volume":"89","author":"Filho","year":"2011","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oret.2024.04.016_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ophtha.2018.07.027","article-title":"Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor","volume":"126","author":"Obeid","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.04.016_bib11","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2018.02.034","article-title":"Loss to follow-up in patients with proliferative diabetic retinopathy after panretinal photocoagulation or intravitreal anti-VEGF injections","volume":"125","author":"Obeid","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.04.016_bib12","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ajo.2020.03.023","article-title":"Predictors of lost to follow-up in patients being treated for proliferative diabetic retinopathy","volume":"216","author":"Green","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.04.016_bib13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ajo.2020.03.011","article-title":"Loss to follow-up among patients with proliferative diabetic retinopathy in clinical practice","volume":"215","author":"Suresh","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.04.016_bib14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/IAE.0000000000002481","article-title":"Patients presenting emergently with proliferative diabetic retinopathy: follow-up and factors associated with compliance","volume":"40","author":"Hinkle","year":"2020","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.04.016_bib15","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ophtha.2017.12.001","article-title":"The 2016 American Academy of Ophthalmology IRIS\u00ae registry (intelligent research in sight) database: characteristics and methods","volume":"125","author":"Chiang","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.04.016_bib16","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ophtha.2023.02.021","article-title":"Loss to follow-up in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy in the United States in the IRIS\u00ae registry","volume":"130","author":"Khurana","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.04.016_bib17","article-title":"Causes and clinical impact of loss to follow-up in patients with proliferative diabetic retinopathy","volume":"2020","author":"Abdelmotaal","year":"2020","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.oret.2024.04.016_bib18","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.ophtha.2022.07.010","article-title":"Disparities in vision health and eye care","volume":"129","author":"Elam","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.04.016_bib19","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ophtha.2023.06.007","article-title":"The impact of social determinants of health on eye care utilization in a national sample of people with diabetes","volume":"130","author":"Taccheri","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.04.016_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100295","article-title":"Health disparities in lapses in diabetic retinopathy care","volume":"3","author":"Cai","year":"2023","journal-title":"Ophthalmol Sci"},{"key":"10.1016\/j.oret.2024.04.016_bib21","first-page":"513","article-title":"Geographic disparity of severe vision loss \u2014 United States, 2009\u20132013","volume":"64","author":"Kirtland","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.oret.2024.04.016_bib22","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamaophthalmol.2021.4103","article-title":"Lapses in care among patients assigned to ranibizumab for proliferative diabetic retinopathy: a post hoc analysis of a randomized clinical trial","volume":"139","author":"Maguire","year":"2021","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302400191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246865302400191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T08:18:51Z","timestamp":1727684331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246865302400191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S246865302400191X"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2024.04.016","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loss to Follow up in Patients with Proliferative Diabetic Retinopathy Treated with Anti-VEGF Therapy and\/or Panretinal Photocoagulation in the United States","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}